secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2022-02-09T23:59:59+00:00
Accession:  0001493152-22-003539
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic launches new OT-101 corporate presentation; JV re-IPO funding on track
--------------------------------------------------------------------------------

- New corporate presentation deployed Feb 7, 2022, covering OT-101 therapeutic programs.
- OT-101 program on track to be fully funded by JV for re-IPO, per filing.
- No financial figures or milestones disclosed in the 8-K or attached exhibit.
- Presentation attached as Exhibit 99.1 but content not available for review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315222003539/0001493152-22-003539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315222003539/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-003539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer